Secondary Brain Injury
Published in The Lancet Neurology
In adult patients (18-80 years) with primary spontaneous supratentorial intracerebral hemorrhage, does deferoxamine mesylate (32 mg/kg/day for 3 days) initiated within 24 hours, compared with placebo, show sufficient promise of improving functional outcome (mRS 0-2) at 90 days to warrant a phase 3 trial (i.e., not futile)?
More topics:
- Acute Blood Pressure Control
- Anti-fibrinolytic Therapy
- Anticoagulant Reversal
- Anticoagulation Reversal
- Antiplatelet Therapy Complications
- Craniotomy
- Deferoxamine
- External Ventricular Drain (EVD)
- Factor VIIa
- Fever Prevention
- Fresh Frozen Plasma (FFP)
- Glucose Control
- Hematoma Evacuation
- Hematoma Expansion
- Hemostasis
- Imaging Biomarkers
- Insulin Therapy
- Intraventricular Hemorrhage
- Iron Chelation
- Ischemic Stroke Management
- Minimally Invasive Surgery
- Neurocritical Care
- Neuroprotection
- Neurosurgical Intervention
- Prothrombin Complex Concentrate (PCC)
- Reversal Agents
- Secondary Brain Injury
- Supportive Care
- Temperature Management
- Thrombolysis (Alteplase)
- Tranexamic Acid
- Warfarin Reversal